Francesca Romana Giglioli1, Lidia Strigari2, Riccardo Ragona3, Giuseppina R Borzì4, Elisabetta Cagni5, Claudia Carbonini6, Stefania Clemente7, Rita Consorti8, Randa El Gawhary9, Marco Esposito10, Maria Daniela Falco11, David Fedele12, Christian Fiandra3, Maria Cristina Frassanito13, Valeria Landoni2, Gianfranco Loi14, Elena Lorenzini15, Maria Rosa Malisan16, Carmelo Marino17, Enrico Menghi18, Barbara Nardiello19, Roberta Nigro20, Caterina Oliviero21, Gabriella Pastore22, Mariagrazia Quattrocchi23, Ruggero Ruggieri24, Irene Redaelli25, Giacomo Reggiori26, Serenella Russo10, Elena Villaggi27, Marta Casati28, Pietro Mancosu26. 1. A.O.U. Città della Salute e della Scienza di Torino, Torino, Italy. Electronic address: francescaromanagiglioli@gmail.com. 2. Regina Elena Cancer Center IFO, Roma, Italy. 3. Dep. of Oncology, Radiation Oncology Unit, University of Torino, Italy. 4. REM Radioterapia, Catania, Italy. 5. IRCCS - Arcispedale Santa Maria Nuova, Reggio Emilia, Italy. 6. ASST "Grande Ospedale Metropolitano Niguarda", Milano, Italy. 7. Azienda Ospedaliera Universitaria Federico II Napoli, Italy. 8. Fisica Sanitaria ACO San Filippo Neri, Roma, Italy. 9. O. San Pietro Fatebenefratelli, Roma, Italy. 10. Azienda Sanitaria Firenze, Italy. 11. Fondazione Policlinico Tor Vergata, Roma, Italy. 12. Casa di Cura Privata San Rossore, Pisa, Italy. 13. Mater Dei Hospital, C.B.H. Città di Bari Hospital s.p.a., Bari, Italy. 14. A.O.U. Maggiore della Carità di Novara, Italy. 15. U.O. Fisica Sanitaria Azienda USL 1 Massa e Carrara, Italy. 16. Medical Physics Dept, University Hospital of Udine, Italy. 17. Humanitas C.C.O., Catania, Italy. 18. IRCCS - IRST, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy. 19. UPMC San Pietro FBF, Roma, Italy. 20. Ospedale S.Camillo de Lellis, Rieti, Italy. 21. IRCCS CROB Rionero in Vulture (OZ), Italy. 22. Ecomedica Empoli, Italy. 23. S.C. Fisica Sanitaria USL 2 Lucca, Italy. 24. Ospedale Sacro Cuore - don Calabria, Negrar (VR), Italy. 25. A.O. San Gerardo di Monza, Italy. 26. Medical Physics Unit of Radiotherapy Dept. Humanitas Clinical and Research Hospital, Rozzano (MI), Italy. 27. AUSL Piacenza, Italy. 28. AOU Careggi, Firenze, Italy.
Abstract
PURPOSE: A large-scale multi-institutional planning comparison on lung cancer SABR is presented with the aim of investigating possible criticism in carrying out retrospective multicentre data analysis from a dosimetric perspective. METHODS: Five CT series were sent to the participants. The dose prescription to PTV was 54Gy in 3 fractions of 18Gy. The plans were compared in terms of PTV-gEUD2 (generalized Equivalent Uniform Dose equivalent to 2Gy), mean dose to PTV, Homogeneity Index (PTV-HI), Conformity Index (PTV-CI) and Gradient Index (PTV-GI). We calculated the maximum dose for each OAR (organ at risk) considered as well as the MLD2 (mean lung dose equivalent to 2Gy). The data were stratified according to expertise and technology. RESULTS: Twenty-six centers equipped with Linacs, 3DCRT (4% - 1 center), static IMRT (8% - 2 centers), VMAT (76% - 20 centers), CyberKnife (4% - 1 center), and Tomotherapy (8% - 2 centers) collaborated. Significant PTV-gEUD2 differences were observed (range: 105-161Gy); mean-PTV dose, PTV-HI, PTV-CI, and PTV-GI were, respectively, 56.8±3.4Gy, 14.2±10.1%, 0.70±0.15, and 4.9±1.9. Significant correlations for PTV-gEUD2 versus PTV-HI, and MLD2 versus PTV-GI, were observed. CONCLUSIONS: The differences in terms of PTV-gEUD2 may suggest the inclusion of PTV-gEUD2 calculation for retrospective data inter-comparison.
PURPOSE: A large-scale multi-institutional planning comparison on lung cancer SABR is presented with the aim of investigating possible criticism in carrying out retrospective multicentre data analysis from a dosimetric perspective. METHODS: Five CT series were sent to the participants. The dose prescription to PTV was 54Gy in 3 fractions of 18Gy. The plans were compared in terms of PTV-gEUD2 (generalized Equivalent Uniform Dose equivalent to 2Gy), mean dose to PTV, Homogeneity Index (PTV-HI), Conformity Index (PTV-CI) and Gradient Index (PTV-GI). We calculated the maximum dose for each OAR (organ at risk) considered as well as the MLD2 (mean lung dose equivalent to 2Gy). The data were stratified according to expertise and technology. RESULTS: Twenty-six centers equipped with Linacs, 3DCRT (4% - 1 center), static IMRT (8% - 2 centers), VMAT (76% - 20 centers), CyberKnife (4% - 1 center), and Tomotherapy (8% - 2 centers) collaborated. Significant PTV-gEUD2 differences were observed (range: 105-161Gy); mean-PTV dose, PTV-HI, PTV-CI, and PTV-GI were, respectively, 56.8±3.4Gy, 14.2±10.1%, 0.70±0.15, and 4.9±1.9. Significant correlations for PTV-gEUD2 versus PTV-HI, and MLD2 versus PTV-GI, were observed. CONCLUSIONS: The differences in terms of PTV-gEUD2 may suggest the inclusion of PTV-gEUD2 calculation for retrospective data inter-comparison.
Authors: Christos Moustakis; Oliver Blanck; Fatemeh Ebrahimi; Mark Ka Heng Chan; Iris Ernst; Thomas Krieger; Marciana-Nona Duma; Markus Oechsner; Ute Ganswindt; Christian Heinz; Horst Alheit; Hilbert Blank; Ursula Nestle; Rolf Wiehle; Christine Kornhuber; Christian Ostheimer; Cordula Petersen; Gerhard Pollul; Wolfgang Baus; Georg Altenstein; Eric Beckers; Katrin Jurianz; Florian Sterzing; Matthias Kretschmer; Heinrich Seegenschmiedt; Torsten Maass; Stefan Droege; Ulrich Wolf; Juergen Schoeffler; Uwe Haverkamp; Hans Eich; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2017-09-15 Impact factor: 3.621
Authors: Christos Moustakis; Oliver Blanck; Fatemeh Ebrahimi Tazehmahalleh; Mark Ka Heng Chan; Iris Ernst; Thomas Krieger; Marciana-Nona Duma; Markus Oechsner; Ute Ganswindt; Christian Heinz; Horst Alheit; Hilbert Blank; Ursula Nestle; Rolf Wiehle; Christine Kornhuber; Christian Ostheimer; Cordula Petersen; Gerhard Pollul; Wolfgang Baus; Georg Altenstein; Eric Beckers; Katrin Jurianz; Florian Sterzing; Matthias Kretschmer; Heinrich Seegenschmiedt; Torsten Maass; Stefan Droege; Ulrich Wolf; Juergen Schoeffler; Uwe Haverkamp; Hans Theodor Eich; Matthias Guckenberger Journal: Strahlenther Onkol Date: 2017-05-31 Impact factor: 3.621